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Insight into determinants of 
substrate binding and transport in a 
multidrug efflux protein
Kamela O. Alegre, Stephanie Paul, Paola Labarbuta & Christopher J. Law
Multidrug resistance arising from the activity of integral membrane transporter proteins presents a 
global public health threat. In bacteria such as Escherichia coli, transporter proteins belonging to the 
major facilitator superfamily make a considerable contribution to multidrug resistance by catalysing 
efflux of myriad structurally and chemically different antimicrobial compounds. Despite their clinical 
relevance, questions pertaining to mechanistic details of how these promiscuous proteins function 
remain outstanding, and the role(s) played by individual amino acid residues in recognition, binding 
and subsequent transport of different antimicrobial substrates by multidrug efflux members of the 
major facilitator superfamily requires illumination. Using in silico homology modelling, molecular 
docking and mutagenesis studies in combination with substrate binding and transport assays, we 
identified several amino acid residues that play important roles in antimicrobial substrate recognition, 
binding and transport by Escherichia coli MdtM, a representative multidrug efflux protein of the major 
facilitator superfamily. Furthermore, our studies suggested that ‘aromatic clamps’ formed by tyrosine 
and phenylalanine residues located within the substrate binding pocket of MdtM may be important for 
antimicrobial substrate recognition and transport by the protein. Such ‘clamps’ may be a structurally 
and functionally important feature of all major facilitator multidrug efflux proteins.
The phenomenon of multidrug resistance – a serious global public health threat-arises principally from active 
efflux of drugs out of the cell cytoplasm by proteins that are integral membrane transporters. The ‘transportome’ 
of most bacteria contains numerous drug efflux proteins1, some of which are driven by energy released by ATP 
hydrolysis (the primary active transporters) and others by the energy stored in electrochemical gradients (the 
secondary active transporters).
The majority of bacterial drug efflux proteins belong to the ubiquitous, large and diverse major facil-
itator superfamily (MFS) of secondary active transporters2. Although sequence similarity among the MFS is 
generally poor, all appear to follow the same structural template, their architecture consisting of either 12- or 
14-transmembrane (TM) α -helices that are separated into six- or seven-helix bundle N- and C-terminal domains, 
respectively, related by a pseudo twofold symmetry and connected by a long cytoplasmic loop3. The N- and 
C-terminal halves of the transporter saddle a central substrate translocation pore, and both the N- and C-tails of 
the protein are located inside the cell. This structural arrangement implies that MFS proteins function via a single 
binding site, alternating access mechanism that is accompanied by a rocker switch-like movement of the two 
halves of the transporter, permitting access to the binding site(s) to swap between cytoplasm and periplasm4. The 
rocker switch mechanism supports at least three major conformational states during a dynamic transport cycle: 
a cytoplasmic or inward-facing conformation (Cin), an outward-facing one (Cout), and a more compact, occluded 
conformation (Cocc) in the intermediate state4.
Six families within the embrace of the MFS contain multidrug efflux transporters5, the most frequently occur-
ring of which are those of the 12 or 14 TM segment drug/H+ antiporter families (DHA1 and DHA2, respectively) 
that use the electrochemical ion gradient to drive drugs out of the cell6. In stark contrast to the stringent spec-
ificity for single substrates within a diverse pool of substrate types (including ions, sugars, organic phosphates, 
neurotransmitters, nucleosides, amino acids and peptides) displayed by most members of the MFS, the multi-
drug transporters of the superfamily are polyspecific and can handle and extrude a remarkably diverse range of 
substrates7. Such substrate promiscuity imparts clinical significance to these proteins in that they can represent a 
barrier to successful treatment of infection.
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Extensive biochemical studies of the prototypical Escherichia coli MFS drug/H+ antiporter, MdfA, suggested 
the structural basis of substrate promiscuity lies in the presence of a large, flexible and complex substrate recog-
nition cavity within the protein, which permits different substrates to interact with different regions of the cavity, 
and to form different interactions with it7–10. Interactions between neutral or zwitterionic substrates and the cavity 
occur primarily via low-specificity hydrophobic interactions, while electrostatic interactions between substrate 
and a membrane-embedded, negatively charged amino acid side chain of the protein are seemingly important 
for the transport of cationic compounds10–14. The picture is further complicated by evidence that two dissimilar 
substrates can bind simultaneously to distinct but allosterically linked sites within the transporter15. Although 
the crystal structure of EmrD, an E. coli MdfA homologue, captured in occluded conformation supports the 
notion of a large, hydrophobic, substrate-recognition cavity, the lack of any substrate molecule resolved in the 
structure precluded any detailed interpretation of a structural basis for substrate polyspecificity in this multidrug 
efflux representative of the MFS16. Recently, however, high-resolution structures of an inward-facing conforma-
tion of MdfA in complex with substrate have been reported17 and these have provided valuable insight into the 
substrate-binding mode and transport mechanism of MFS multidrug efflux proteins in general. However, despite 
this much enhanced understanding, questions pertaining to multidrug recognition and transport by members of 
the MFS are still outstanding; for example, are the same residues involved in substrate recognition and binding 
in other conformations of the protein? Moreover, are the same residues involved in recognition of all substrate 
types the protein is capable of transporting? We have attempted to shed light on these questions by performing 
a combination of in silico, biochemical, and mutagenesis studies on the E. coli MFS drug/H+ antiporter MdtM.
MdtM is a versatile and close relative of MdfA18 that not only renders cells expressing it from multicopy plas-
mid resistant to a range of antimicrobial compounds19–22 but also functions physiologically as a monovalent metal 
cation/H+ antiporter with a role in pH homeostasis in alkaline environments23 and in protection of cells against 
the cytotoxic effects of bile salts24. We generated an homology model of MdtM in occluded conformation for use 
in molecular docking studies of two known antimicrobial substrates of the transporter, one neutral at physiologi-
cal pH (chloramphenicol) and the other (tetraphenylphosphonium or TPP+) cationic, with the aim of identifying 
amino acid side chains that function in recognition and binding of the differently charged substrates. The results 
of the in silico studies were used to guide subsequent mutagenesis experiments that tested the effects of individual 
mutations on the drug efflux phenotype, and the substrate binding and transport characteristics of the protein.
Results
Homology model of MdtM in occluded conformation. The homology model of MdtM, which repre-
sents the transporter in a compact and apparently occluded conformation that may represent a transition state of 
the transport cycle3, consisted of 379 residues (14–392) corresponding to residues 9–382 of the EmrD template 
structure (Fig. 1). The sequence identity between EmrD and MdtM over these residues was 20%, compared to 
the overall sequence identity and similarity between MdtM and EmrD of 23% and 43%, respectively. The N- 
and C-terminal cytoplasmic tail regions of MdtM (residues 1–13 and 393–410, respectively) were not modelled 
because the equivalent residues were not resolved in the EmrD crystallographic structure.
The optimised MdtM model was subjected to computational validation analyses to test its reliability and con-
sistency. The stereochemical quality of the model was assessed using PROCHECK validation software, and the 
resulting Ramachandran plot output revealed that 96.4% of the non-glycine and non-proline amino acid residues 
of the model were located in the favoured and additionally allowed regions, with only 1.8% each in the gener-
ously allowed and disallowed regions (Supplementary Fig. S1). The residues in the latter two regions of the plot 
are located in periplasmic or cytoplasmic loops of the MdtM model; these loop regions are not expected to be 
perfectly predicted for membrane proteins. All the main chain parameters of the model are within the typically 
Figure 1. Homology model of MdtM in occluded conformation. (a) viewed parallel to the plane of the 
membrane with the cytoplasmic side at the bottom and the periplasmic side at the top. The N- and C-termini 
are labelled, and the transmembrane helices are numbered. (b) viewed perpendicular to the plane of the 
membrane from the periplasmic side. Figure was produced using the PyMOL Molecular Graphics System 
(Schrödinger, LLC).
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expected bandwidths and the overall G-factor was − 0.22. The same analysis performed on the crystallographic 
structure of the EmrD template yielded similar results, thereby instilling confidence in the overall correctness of 
the MdtM model.
The overall architecture of the model is typical of MFS transporters3 and consists of 12 TM α -helices of gen-
erally different lengths arranged into two six-helix, N- and C-terminus bundles that are joined on the cytoplas-
mic side of the protein by a long loop that extends from TM6 to TM7 (Fig. 1). As shown in Fig. 1b, eight of the 
TM helices (TM helices 1, 2, 4 and 5 in the N-terminal half of the protein and TM helices 7, 8, 10 and 11 in the 
C-terminal half) form a palisade around a large, central cavity that represents the substrate-binding region of the 
transporter. Similar to the crystallographic structures of EmrD16 and MdfA17, several bulky, aromatic, and polar 
uncharged residues line the binding cavity of the MdtM model and impart a generally hydrophobic character 
upon it; at least some of these cavity residues are likely to function in recognition and binding of the drug sub-
strates transported by MdtM.
Comparison of our MdtM model with the inward-open MdfA crystal structure17 revealed similarities with 
respect to the location of individual residues important for transporter function. In MdfA, two membrane 
embedded, negatively charged residues (E26 and D34) located in TM1, and a positively charged arginine in TM4 
(R112) have been implicated in transport function12,17; indeed, a positive charge at position 112 is essential for 
MdfA function25. As shown in Supplementary Fig. 2, the equivalent residues (D22, D30, and R108) in the MdtM 
model are also located in TM1 and TM4 and at a very similar depth within the membrane as the corresponding 
MdfA residues. In MdfA a glutamate (E132) that functions in substrate recognition25 caps the cytoplasmic end of 
TM4 and an equivalent glutamate (E128) is found in the same location in our MdtM model.
Molecular docking of substrates to the MdtM model. The crystal structures of MdfA revealed amino 
acid residues involved in substrate binding to the Cin conformation of the protein17 and, considering the close 
homology of MdtM to MdfA21, it is likely that the equivalent residues in MdtM also function in substrate bind-
ing. However, it is unknown if the same residues remain involved as the transporter undergoes conformational 
change. We therefore used our model of MdtM for molecular docking studies of two representative substrates of 
the transporter to identify residues potentially involved in binding of substrate to the occluded state.
Docking of the TPP+ and chloramphenicol substrate molecules enabled visualization of the spatial relation-
ship between the whole MdtM molecule and the substrates (Fig. 2). Both substrates bound in the central cavity of 
the transporter, but with a clear bias toward the N-terminal domain, in a large pocket formed by the membrane 
spanning regions of TM1, TM2, TM4 and TM5. Furthermore, although the binding site of each substrate was 
distinct, some overlap was apparent. These observations are largely consistent with the results of a previous study 
of substrate binding to MdfA that suggested the existence of distinct but interacting binding sites within a large, 
flexible substrate recognition pocket of the protein that could accommodate the simultaneous binding of TPP+ 
and chloramphenicol15; our docking studies with MdtM suggest this is a common feature of multidrug efflux 
members of the MFS.
The results of docking TPP+ to MdtM revealed that the majority of the molecular interactions between the 
substrate and the protein were hydrophobic in character, with a complete absence of any H-bonding or polar 
interactions (Supplementary Table S1). Hydrophobic interactions occurred between TPP+ and the MdtM C116, 
A119, A140 and I141 residues. The aromatic side chains of two tyrosine residues, Y26 and Y123, interacted with 
two of the four phenyl rings of TPP+ via π -π interactions to form an ‘aromatic clamp’, like a pair of tongs, around 
the substrate molecule (Fig. 2a). The docking study also suggested D22, T120 and S144 of MdtM as interaction 
partners of the substrate (Supplementary Table S1), with the oxygen atoms of those amino acid side chains per-
haps involved in making anion-π interactions with the edge of the TPP+ phenyl rings (Fig. 2a).
In contrast to the absence of H-bonding and polar interactions between TTP+ and MdtM, these types of 
interactions were prevalent when chloramphenicol was docked to the transporter (Supplementary Table S2). 
H-bonding was observed between the substrate and the S144 side chain of MdtM, polar interactions were made 
with D22, Y57, S144 and Q257, and the A119 side chain also interacted the substrate (Fig. 2b). Additionally, 
hydrophobic interactions formed between chloramphenicol and the C116 and I148 residues of MdtM. An aro-
matic triad consisting of Y26, Y57 and F253 interacted with the chloramphenicol molecule via π -π interactions. 
The aromatic rings of Y57 and F253 appeared to act as a ‘clamp’ to hold the substrate in place in the pore of the 
transporter. Notably, the interaction between chloramphenicol and Y26, and a further interaction that occurred 
between substrate and the acidic D30 residue of MdtM in our docking study were consistent with observations 
from the substrate-bound, inward-open MdfA crystal structure in which the equivalent conserved residues (Y30 
and E34) of MdfA were also shown to function in chloramphenicol binding17.
The in silico studies described above were performed using a static model that represents the MdtM protein 
structure at one particular phase of the transport cycle. In reality, MdtM is a dynamic protein that undergoes 
conformational change during the drug efflux event4,26; it is therefore probable that substrate interacts with other 
residues as it initially ‘explores’ the binding cavity of the protein27,28 and subsequently translocates through the 
pore during the transport event. Such substrate-interacting residues have been identified in other MFS transport-
ers9,11,17,25,29–33, and that information along with our MdtM model was used to guide identification of functionally 
related but not necessarily conserved residues in the latter34. This approach yielded an additional five residues 
(Q33, T120, M232, F261, and K342) as candidates for functioning in a substrate recognition/binding role in 
MdtM (Supplementary Fig. S3; Supplementary Table S3).
All candidate substrate-interacting residues were mutated individually to alter amino acid side chain charge 
and/or size, and the effects of each mutation on the efflux phenotype of E. coli that overexpressed each mutant 
transporter was tested to provide a guide for further studies that investigated: (i) binding of substrate to puri-
fied mutant protein; and (ii) transport activity of mutant protein in inverted vesicles. Additionally, to test our 
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‘aromatic clamp’ hypothesis, two double mutants (Y26A/Y123A and Y57A/F253A) were engineered and tested, 
and a Y26F/F253Y double mutant tested the effect of exchanging the position of these two aromatic residues.
Effect of MdtM mutations on E. coli efflux phenotype. The results of the docking studies were used to 
inform design of a series of 30 MdtM mutants (27 single and 3 double mutants) and these mutant proteins were 
used in subsequent in vivo experiments to elucidate the role(s) of individual amino acid side chains in substrate 
recognition, binding, and transport. Initial studies focused on characterisation of the chloramphenicol and TPP+ 
efflux phenotypes of E. coli ∆ mdtM single-deletion mutant cells that overproduced each mutant transporter from 
plasmidic DNA by determination of IC50 values for the substrates. Cells that overexpressed the MFS Pi/glycerol 
3-phosphate antiporter GlpT35 – a substrate-specific protein that does not possess ability to bind or transport 
chloramphenicol or TPP+-were used as a negative control; the mean (±s.d.) IC50 values for chloramphenicol and 
TPP+ in these negative control cells were 0.19 (± 0.02) μg/mL and 0.21 (± 0.01) mg/mL, respectively (Fig. 3). Cells 
that overexpressed plasmidic, wild type MdtM in the ∆ mdtM background showed ~2-fold increase in resistance 
to both antimicrobials tested with IC50 values of 0.39 (± 0.02) μg/mL for chloramphenicol and 0.45 (± 0.04) mg/
mL for TPP+. To exclude the effect that any significant differences in expression level of each protein could have 
on the IC50 values, Western blots of cell membranes were performed and these provided confirmation that expres-
sion levels of wild type and mutant MdtM protein and the GlpT negative control were similar (Supplementary 
Fig. S4).
Figure 2. Molecular docking of substrates to the MdtM homology model. (a) docking of TPP+ to MdtM 
in occluded conformation. The TPP+ substrate is depicted as a sphere model with carbon atoms coloured 
grey and the interacting protein side chains as yellow sticks. (b) docking of chloramphenicol to MdtM in 
occluded conformation. The substrate is depicted as spheres (with carbon atoms coloured grey, oxygen 
atoms red, nitrogen atoms blue and chlorine atoms white). Interacting protein side chains are represented as 
yellow sticks. In (a,b), the protein is viewed parallel to the membrane plane with the periplasmic side at the 
top. Transmembrane helices (TMs) that constitute the N-terminal half of the protein are shaded in sky blue 
and those of the C-terminal half in grey. Figure was produced using the PyMOL Molecular Graphics System 
(Schrödinger, LLC).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:22833 | DOI: 10.1038/srep22833
Comparison of the IC50 values for TPP+ and chloramphenicol (Fig. 3a,b, respectively) revealed that mutation 
of MdtM residues suggested by the in silico docking studies to play a role in substrate binding tended to have a 
more pronounced effect on the E. coli TPP+ efflux phenotypes with the majority of the 30 MdtM mutants showing 
an increase in susceptibility towards the cationic antimicrobial (Fig. 3a). An analysis of the IC50 data was per-
formed using an unpaired t-test to identify those mutations that resulted in a statistically significant decrease or 
increase in resistance to TPP+ compared to wild type MdtM. To avoid the effects of small differences in expression 
levels of MdtM influencing the analysis the alpha level was set to 0.01 and differences in IC50 values were consid-
ered to be significant if P < 0.01. Using this analysis, five of the MdtM mutants (D22A, A119C, F261A, K342E and 
the Y26F/F253Y double mutant) exhibited a significant loss of function compared to wild type protein, with IC50 
values for TPP+ that did not differ significantly from that of the GlpT negative control (Fig. 3a). In addition to the 
loss of function efflux phenotypes, three of the MdtM mutations (Y26A, F253A, and Q257E) yielded a significant 
(P < 0.01) gain of function with respect to resistance against TPP+, with each showing ~1.5-fold increase in IC50 
for the antimicrobial, and with the largest mean increase in resistance associated with the Q257E mutation.
In contrast to the generally deleterious effect that mutagenesis of MdtM had on the TPP+ IC50 values, the 
chloramphenicol efflux phenotypes appeared much more resilient towards mutagenesis and only two of the muta-
tions tested (D22A and the Y57A/F253A double mutant) exhibited a significant (P < 0.01) loss of resistance to the 
antibiotic (Fig. 3b). Significant (P < 0.01) gain of function was observed for three mutants tested (Y26A, C116V, 
and the Y26A/Y123A double mutant) with a ~2.5-fold and ~2-fold increase in resistance to chloramphenicol con-
ferred by the Y26A and Y26A/Y123A mutations, respectively. To ascertain whether the loss or gain of function 
observed from the efflux phenotype assays emanated from changes in substrate binding affinity and/or transport 
activity of the MdtM mutants, and to further test our ‘aromatic clamp’ hypothesis, we performed binding studies 
on purified protein in DDM detergent solution and transport measurements on inverted vesicles prepared from 
E. coli cells that overexpressed mutant transporter.
Figure 3. Antimicrobial efflux phenotypes of E. coli BW25113 cells that overexpressed wild type or mutant 
MdtM, or GlpT negative control, as determined by IC50 values. (a) IC50 values for TPP+ as antimicrobial 
substrate. (b) IC50 values for chloramphenicol as antimicrobial substrate. In (a,b) bars and error bars represent 
the mean ± s.d. of at least eight separate measurements. (**) denotes IC50 values that represent a statistically 
significant (P < 0.01) gain or loss of efflux function.
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Loss of function efflux phenotypes retained MdtM substrate-binding activity. Apparent binding 
dissociation constants (Kdapp) of purified wild type and mutant MdtM protein for TPP+ and chloramphenicol 
substrates were extracted from non-linear regression analysis of steady-state intrinsic tryptophan fluorescence 
quenching data (Supplementary Figs S5 and S6). The analysis revealed that loss of function observed in the efflux 
phenotype assays was not derived from a loss of MdtM substrate binding activity, as no single residue tested 
was essential for binding of either of the substrates to the protein (Tables 1 and 2). Substrate binding affinity of 
wild type protein for the substrates was in the nM range, with Kdapp values for TPP+ and chloramphenicol of 400 
(±145) nM (Table 1) and 22 (± 4) nM (Table 2), respectively. The mutant proteins also possessed nM binding 
affinities and those mutants associated with gain of function efflux phenotype generally exhibited an increase in 
affinity for substrate compared to wild type protein. Intriguingly, the proposed TPP+ clamp (Y26/Y123), when 
substituted to alanine, appeared to drastically lower the Kdapp for chloramphenicol to ~1 nM, whereas alanine sub-
stitution of the chloramphenicol clamp (Y57/F253) increased the Kdapp of the neutral antibiotic about 17.5-fold 
(Table 2). Although the effect of the Y26A/Y123A double substitution on binding of TPP+ was not as dramatic 
and resulted in about a 2-fold decrease in Kdapp, the Y57A/F253A chloramphenicol clamp double mutation 
resulted in a significant decrease of the Kdapp for the cationic substrate to ~56 nM (Table 1). However, in the latter 
case, the apparent tighter binding of TPP+ to the mutant did not translate into a gain of function efflux phenotype 
(Fig. 3a).
The relationship between substrate binding affinity and loss of function efflux phenotype was less clear; while 
the A119C and Y57A/F253A mutations resulted in substantially decreased affinity for TPP+ and chloramphen-
icol, respectively, compared with wild type MdtM, the D22A, F261A and Y26F/F253Y mutants all bound TPP+ 
with affinity similar to that of the wild type protein (Tables 1 and 2). However, substitution of positively-charged 
K342 with acidic glutamate actually enhanced affinity of the transporter for TPP+ substrate (Table 1) even though 
transport capability of the mutant was severely compromised (Fig. 4). Retention of substrate binding activity by 
all the MdtM mutants tested indicated that loss of function efflux phenotype derived from transport dysfunction, 
probably due to inability of the protein to either undergo conformational change or facilitate proton transfer.
Loss of efflux function stems from defects in the transport phase of the MdtM reaction cycle. 
To examine the effects of mutagenesis on TPP+ and chloramphenicol efflux by MdtM we analysed transport activ-
ity of wild type and mutant transporter using a vesicle-based assay that reported proton-driven antiport activity 
as a dequench of acridine orange fluorescence. As shown in Figs 4 and 5, while vesicles prepared from cells that 
overexpressed wild type MdtM were clearly TPP+ and chloramphenicol transport-active (as revealed by ~20–30% 
dequench of the initial fluorescence signal upon addition of substrate), negative control vesicles that harboured 
GlpT produced negligible quenching of the fluorescence signal when TPP+ was used as substrate (Fig. 4). When 
MdtM protein Apparent Kd (nM) R-squared
WT 400 ± 145 0.96
D22A 449 ± 54 0.99
Y26A 147 ± 24 0.99
A119C 1083 ± 73 0.98
F253A 222 ± 40 0.97
Q257E 257 ± 76 0.98
F261A 415 ± 56 0.99
K342E 147 ± 11 0.96
Y26A/Y123A 206 ± 46 0.96
Y26F/F253Y 498 ± 52 0.98
Y57A/F253A 56 ± 10 0.98
Table 1.  Binding affinity of wild type and mutant MdtM for TPP+. Kdapp values represent the mean ± s.d. of 
three measurements. R-squared values indicate the fit of a non-linear regression model to the substrate binding 
data presented in Supplementary Fig. S5.
MdtM protein Apparent Kd (nM) R-squared
WT 22 ± 4 0.97
D22A 20 ± 4 0.96
Y26A 4 ± 1 0.96
C116V 4 ± 2 0.97
Y26A/Y123A 1 ± 0.5 0.97
Y26F/F253Y 18 ± 6 0.91
Y57A/F253A 387 ± 115 0.96
Table 2.  Binding affinity of wild type and mutant MdtM for chloramphenicol. Kdapp values represent the 
mean ± s.d. of three measurements. R-squared values indicate the fit of a non-linear regression model to the 
substrate binding data presented in Supplementary Fig. S6.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:22833 | DOI: 10.1038/srep22833
chloramphenicol was added to the negative control, a small fluorescence dequench due to activity of chromosom-
ally encoded transporters capable of efflux of the antibiotic was apparent (Fig. 5). In all the experiments, addition 
of the ionophore carbonyl cyanide 3-chlorophenylhydrazone (CCCP) to dissipate the proton electrochemical gra-
dient caused an instantaneous dequenching of the fluorescence signal, thus providing evidence that the inverted 
vesicles had maintained integrity over the lifetime of the assay.
Although the D22A and K342E mutants appeared to retain some residual transport activity for TPP+, the 
A119C, F261A, and Y26F/F253Y mutations effectively abolished transport of the same substrate (Fig. 4), thus 
indicating the importance of these residues in MdtM for the translocation of cationic antimicrobials across the 
Figure 4. MdtM-dependent TPP+/H+ exchange in inverted vesicles. Transport measurements were 
performed by monitoring the fluorescence quench/dequench of acridine orange upon addition of TPP+ to 
inverted vesicles prepared from E. coli TO114 cells that overproduced recombinant wild type or mutant MdtM 
or, as a control, GlpT. Respiration-dependent generation of ΔpH (acid inside) was established by addition 
of lactate as indicated and once the fluorescence quench of acridine orange reached a steady state, TPP+ 
substrate was added. Addition of 100 μM CCCP at the time indicated completely dissipated ΔpH. The traces are 
representative of experiments performed in triplicate on at least two separate preparations of inverted vesicles.
www.nature.com/scientificreports/
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membrane. In contrast, the Y26A, F253A, and Q257E mutants exhibited enhanced TPP+ transport activity, with 
the Y26A and Q257E mutants in particular exhibiting a greater dequench of the initial fluorescence signal upon 
addition of the substrate than did wild type protein. Wild type transport activity for TPP+ was apparent for the 
Y26/Y123 and Y57/F253 double alanine substitutions (Fig. 4). Similarly, as shown in Fig. 5, while the MdtM 
Y26A, C116V, and Y26A/Y123A mutations associated with E. coli phenotypes that displayed gain of function with 
respect to chloramphenicol resistance retained ability to transport the antibiotic, the alanine substitutions of D22 
and Y57/F253 resulted in almost total loss of chloramphenicol transport activity. Exchange of the positions of the 
tyrosine and phenylalanine residues in the Y26F/F253Y double mutant had negligible effect on chloramphenicol 
transport (Fig. 5). Taken together with the results of the efflux phenotype and substrate binding assays, these 
results (which are summarised in Supplementary Tables S4 and S5) clearly revealed that mutation of putative 
substrate-interacting residues in MdtM had a greater impact on the transport stage of the reaction cycle rather 
than the substrate-binding stage.
Discussion
Recent crystal structures of E. coli multidrug efflux protein MdfA with substrate bound have placed previous 
biochemical studies of multidrug antiporters of the MFS in a structural context and have revealed the mode 
Figure 5. MdtM-dependent chloramphenicol/H+ exchange in inverted vesicles. Transport measurements 
were performed by monitoring the fluorescence quench/dequench of acridine orange upon addition of 
chloramphenicol to inverted vesicles prepared from E. coli TO114 cells that overproduced recombinant wild 
type or mutant MdtM or, as a control, GlpT. Respiration-dependent generation of ΔpH (acid inside) was 
established by addition of lactate as indicated and once the fluorescence quench of acridine orange reached a 
steady state, chloramphenicol substrate was added. Addition of 100 μM CCCP at the time indicated completely 
dissipated ΔpH. The traces are representative of experiments performed in triplicate on at least two separate 
preparations of inverted vesicles.
www.nature.com/scientificreports/
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of substrate binding to the inward-facing conformation of the protein as well as suggesting a general transport 
mechanism17. However, it is unclear if the integrity of the binding site is retained or if different residues become 
involved in substrate binding as the transporter undergoes the conformational change necessary for transport. To 
investigate this, we explored the structural and functional features of the binding site(s) of MdtM, a close E. coli 
homologue of MdfA, in an occluded conformation that represented the protein during an intermediate stage of 
the transport cycle using a combination of in silico docking and site-directed mutagenesis studies. The observa-
tion that only three (Y26, Y57, and A119) of the 17 putative substrate-interacting residues identified by docking of 
TPP+ and chloramphenicol to MdtM were shown to interact with both substrates is consistent with the presence 
of distinct but partially overlapping binding sites to accommodate substrates of different structural and chemical 
properties within the transporter15,36.
With the exception of the significant increase in IC50 for both antimicrobials conferred by alanine substitution 
of Y26, and the apparent loss of efflux function associated with the D22A mutation in MdtM, other mutations 
that resulted in a gain or loss of TPP+ efflux function had no significant impact on the chloramphenicol efflux 
phenotype, and vice versa (Fig. 3). For example, although the A119C, F261A, K342E, and Y26F/F253Y muta-
tions in MdtM resulted in loss of resistance to TPP+, the same mutations had no commensurate effect on resist-
ance towards chloramphenicol. This implies that these residues are not crucial for transport activity of MdtM 
per se and that loss of TPP+ efflux function associated with the mutations originated from a defect in binding 
of the cationic substrate. However, because all the MdtM mutants retained TPP+ binding activity, abolition of 
efflux activity probably arose from the inability of TPP+-bound mutant to effect either conformational change 
or to release the cationic substrate. Interestingly, although F261 was not identified by our docking studies as a 
substrate-interacting residue we proposed a functional role for it based on comparison of our homology model of 
MdtM with the crystal structure of the MFS substrate-specific symporter FucP37. In FucP, a phenylalanine residue 
(F308) located in TM8 is important for transport function of that protein38, and F261 was located in a similar 
position on TM8 in our homology model of MdtM.
The differential effect of mutagenesis of the Q257 residue of MdtM on TPP+ and chloramphenicol efflux 
phenotypes may provide a clue as to why MdtM-catalysed transport of the latter appeared more resilient to the 
effects of mutation. Substitution of Q257 with glutamate resulted in an increase in both IC50 and binding affinity 
of cationic TPP+ compared with wild type protein but had no significant effect on IC50 for electrically neutral 
chloramphenicol. We propose that exchange of the amide side chain for an acidic one aids charge neutralisation 
of TPP+ to facilitate its export against the positive-outside membrane potential. Charge neutralisation of lipo-
philic cation substrates plays an important role in substrate recognition and binding in other multidrug binding 
proteins39,40 and it is likely to be a common mechanism employed by drug efflux representatives of the MFS. 
However, such a mechanism would not explain the differential effects of the F253A mutation; we speculate that in 
this case the gain of TPP+ efflux function was due to removal of a restrictive steric effect caused by the phenylala-
nine side chain, and that this promoted tighter binding. Similarly, increased binding affinity due to elimination of 
a sulfhydryl group within the substrate-binding pocket may explain the apparent differential impact of the C116V 
mutation on the chloramphenicol transport activity of MdtM.
The functional importance of acidic residues within the transmembrane spanning regions of MFS multidrug 
transporters is well established and the essential role of MdtM D22 in protection of E. coli cells against chloram-
phenicol and for efflux of cationic antimicrobial substrate by MdtM has been reported before21,23. Though the 
proton-titratable D34 residue of MdfA (which is homologous to MdtM D30) is critical for the substrate binding 
and transport activities of that protein12,17,41, the MdtM D30A or D30N mutations had no significant effect on 
either the TPP+ or chloramphenicol resistance phenotypes (Fig. 3). D34 is proposed to function as a critical 
component of the proton transfer system within MdfA, and its deprotonation upon substrate binding is the 
trigger for conformational change of the transporter17. The apparently non-essential nature of the equivalent 
residue in MdtM for efflux of either neutral or cationic substrate suggests that one or more other residues located 
within the transmembrane spanning region of MdtM possess capacity to compensate for the loss of D30 and 
implies that this conserved amino acid makes different contributions to the transport reaction in the different 
transporters.
A differential role for conserved residues within MdtM and MdfA was highlighted most strikingly by alanine 
substitution of a conserved tyrosine, Y26, in TM1 of MdtM. Alanine substitution of the equivalent residue (Y30) 
in MdfA abolished binding of chloramphenicol and it was proposed that Y30 might act as part of a proton-wire17. 
The gain of efflux function for both TPP+ and chloramphenicol conferred by the Y26A mutation clearly dis-
counted a role for the tyrosine in proton transfer in MdtM. This contention was supported by the observation that 
removal of the hydroxyl group by replacement of Y26 with phenylalanine retained a wild type or even enhanced 
efflux phenotype. We suggest that removal of the bulky aromatic ring(s) in the Y26A and Y26A/Y123A mutants 
relieved a steric hindrance and that the enhanced efflux activity associated with the mutation(s) was a conse-
quence of the increased affinity for substrate.
Docking studies revealed that Y26 and Y123 formed an ‘aromatic clamp’ around TPP+ in the MdtM 
substrate-binding site, and Y57 and F253 appeared to form a similar ‘clamp’ around chloramphenicol. 
Mutagenic exchange of the tyrosine and phenylalanine residues in the Y26F/F253Y mutant abrogated TPP+ 
efflux, whereas the same mutagenesis had no impact on chloramphenicol efflux phenotype. In contrast, while 
the Y57A/F253A double mutation severely compromised chloramphenicol transport, there was no substan-
tial effect on TPP+ efflux activity. These observations suggest that the spatial arrangement of the tyrosine 
and phenylalanine residues is an important recognition factor for cationic and neutral antimicrobial sub-
strates in MdtM. It is therefore tempting to speculate that ‘aromatic clamps’ within the substrate translocation 
pore of MFS multidrug efflux proteins may be an important structural/mechanistic feature of this class of 
transporter.
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Methods
Homology modelling. The homology model of MdtM was generated using the ModPipe42 module of the 
ModWeb automated comparative modelling web-server (http://salilab.org/modbase)43. The amino acid sequence 
of MdtM from E. coli K-12 (UniProtKB P39386) was used as the target input and the ModWeb database of non-re-
dundant chains of three-dimensional structures in the Protein Data Bank (PDB) used as structural templates. 
Initially, a number of models were built for each of the target sequence-template matches. The best-scoring mod-
els as assessed by ModPipe quality score (MPQS)43 and Discrete Optimized Protein Energy (DOPE) statistical 
potential44 were selected for further filtering and quality evaluation. Only those models with quality criteria val-
ues above specified thresholds or an E-value < 10−4 were included in the final model set; four of these were filtered 
as potential candidates for the final model and subjected to additional validation analyses using PROCHECK45 
and WHAT IF46, and visualised by PyMol47. Based on these quality tests, the best-performing model was iden-
tified as one that used the crystal structure of the E. coli multidrug transporter EmrD (PDB code 2GFP)16 as the 
template. This model was loop-optimised with MODELLER48, validated again using PROCHECK45, and then 
used for molecular docking studies.
Molecular docking studies. Molecular docking calculations on the MdtM protein model were carried out 
using DockingServer (http://www.dockingserver.com)49. The MMFF94 force field50 was used for energy min-
imization of the cationic substrate tetraphenylphosphonium (TPP+) and neutral substrate chloramphenicol 
(2,2-dichloro-N-[2-hydroxy-1-hydroxymethyl-2-(4-nitro-phenyl)-ethyl]-acetamide). Gasteiger partial charges 
were added to the ligand atoms. Essential hydrogen atoms, Kollman united atom type charges, and solvation 
parameters were added with the aid of AutoDock tools51. Affinity (grid) maps of 30 × 30 × 30 Å grid points and 
0.375 Å spacing were generated using the Autogrid program51. AutoDock parameter set- and distance-dependent 
dielectric functions were used in the calculation of the van der Waals and the electrostatic terms, respectively. 
Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and the Solis & Wets local 
search method52. Initial position, orientation, and torsions of the ligand molecules were set randomly. Each dock-
ing experiment was derived from 100 different runs that were set to terminate after a maximum of 2500000 
energy evaluations. The population size was set to 150. During the search, a translational step of 0.2 Å, and qua-
ternion and torsion steps of 5 were applied. For each substrate investigated, the docking result with the lowest free 
energy of binding was selected as final.
Bacterial strains, plasmids and site-directed mutagenesis. E. coli BW25113 {rrnB3 ΔlacZ4787 
hsdR514 Δ(araBAD)567 Δ(rhaBAD)568 rph-1} and its ΔmdtM single-deletion mutant were obtained from the 
Keio collection (National BioResource Project, Japan)53. The ΔmdtM deletion mutant was used as the background 
strain for determining IC50 values of cells expressing wild type and mutant MdtM, and GlpT from pBAD/Myc-His 
A vector (Life Technologies). For production of inverted vesicles used in transport assays, E. coli TO114 (a strain 
deficient in the NhaA, NhaB and ChaA antiporters) complemented with plasmidic DNA encoding mutant MdtM 
or GlpT was used. Overproduction of wild type and mutant MdtM, and GlpT for purification and subsequent use 
in substrate-binding assays was performed in E. coli LMG194 (KS272 Δara714 leu::Tn10) transformed with the 
appropriate plasmid21. MdtM mutants were produced using the QuikChange Lightning site-directed mutagenesis 
kit (Agilent Technologies) with wild type mdtM-containing pBAD/Myc-His A vector as the template. The fidelity 
of each mutant construct was verified by DNA sequence analysis.
Determination of IC50 values. The IC50 values of chloramphenicol and TPP+ were determined using 
a plate-based, microtitre assay. An overnight culture of E. coli BW25113 ΔmdtM deletion mutant harbouring 
the plasmidic mdtM was used to inoculate 100 mL of LB liquid medium containing kanamycin (30 μg/mL) and 
carbenicillin (100 μg/mL), then incubated at 37 °C for 2 hours prior to decreasing the temperature to 30 °C. 
Overexpression of plasmidic MdtM was induced at OD600 of 0.7 by addition of 0.002% (w/v) L-arabinose and 
incubation was continued until OD600 of 1.0 was achieved. 104 cfu of this culture were used to inoculate the test 
wells of a pre-prepared 96-well, flat bottom plate. Plates were prepared by adding 200 μl of LB broth containing 
the appropriate antibiotics and 0.002% (w/v) L-arabinose to each of the wells. 100 μl of chloramphenicol or TPP+ 
solution (at initial concentrations of 2.7 μg/mL and 4 mg/mL, respectively) was then added to the first column of 
the plate. After mixing by gentle aspiration, 100 μl of column one was withdrawn and added to column two. This 
serial two-fold dilution procedure was repeated for the remaining test columns. The last three columns of each 
plate were used as blanks. The plates were sealed with gas permeable covers and incubated overnight at 37 °C prior 
to reading the OD600 of each well with a plate reader. IC50s were calculated as described previously22.
Western blots. Inner membranes of E. coli BW25113 ∆ mdtM deletion mutant that overexpressed recombinant 
GlpT, and wild type and mutant MdtM were solubilised by addition of 2.0% (w/v) β -D-dodecylmaltopyranoside 
(DDM), incubated for 1 h at 4 °C then centrifuged at 20,000 × g for 20 min to pellet unsolubilised material. 
Supernatant containing 80 μg of solubilised membrane protein was loaded onto an SDS-PAGE gel of 12% acryla-
mide and electrophoresis performed at 180 V for 1 h prior to transfer of resolved protein to nitrocellulose mem-
brane. Recombinant, histidine-tagged protein was detected using HisProbe-HRP and SuperSignal West Pico 
Chemiluminescent Substrate (Pierce Thermo Scientific) according to the manufacturer’s instructions and visual-
ised with photographic film.
Protein purification. Wild type and mutant MdtM, and GlpT was purified using a protocol described 
previously54.
Substrate binding assays. Substrate-binding affinity of purified MdtM for chloramphenicol or TPP+ 
was determined using intrinsic tryptophan fluorescence quenching as described previously22 except that the 
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buffer system consisted of 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5% (v/v) glycerol and 0.1% (w/v) DDM. Any 
inner filter effect was corrected for as described in55. Data were fitted using non-linear regression analysis with 
SigmaPlot 10 (Systat Software) to allow determination of apparent dissociation constants.
Vesicular transport assays. Assays of chloramphenicol/H+ and TPP+/H+ antiport were conducted by 
measuring the fluorescence quenching/dequenching of the pH-sensitive indicator acridine orange upon addition 
of substrate to energized inverted membrane vesicles generated from antiporter-deficient E. coli TO114 cells that 
overproduced recombinant MdtM or negative control GlpT as described before24.
Cells were grown and inverted vesicles were generated using protocols described before22 and the total mem-
brane protein concentration of the vesicles was determined using the bicinchoninic acid assay (Thermo Scientific 
Pierce). Transport measurements were performed at 25 °C using a Fluoromax-4 fluorometer (Horiba). The assay 
mixture was excited at 492 nm, and the fluorescence emission recorded at 525 nm with excitation and emission 
slits set to 1.5 nm and 2.5 nm, respectively. Inverted membrane vesicles were added to reaction buffer (10 mM 
BisTris propane, pH 7.2, 5 mM MgSO4 and 1 μM acridine orange) in a quartz cuvette to a final concentration of 
0.5 mg/mL membrane protein. Respiration-dependent generation of ΔpH (acid inside) was initiated by addition 
of 2 mM Tris-D-L-lactate and, once a stable ΔpH was established, chloramphenicol or TPP+ was added to a final 
concentration of 100 μM to assess transport activity. The fluorescence dequenching upon addition of substrate 
was monitored for 60 s prior to the addition of 100 μM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) to 
completely dissipate ΔpH and abolish transport.
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